Abstract:BACKGROUND: Inflammatory cytokines like interleukin-6 (IL-6) are implicated in depression, but most studies have hitherto focused on circulating levels of IL-6 rather than its activity. IL-6 trans-signalling is thought to be responsible for most of the pathogenic effects of IL-6 and is implicated in autoimmune diseases like rheumatoid arthritis. We tested the association between a multi-protein-derived measure of IL-6 trans-signalling and clinical and cognitive outcomes in patients with depression. We hypothesised that this novel measure of IL-6 activity/bioavailability would be associated with clinical and cognitive measures previously reported to be associated with inflammation in depression.METHODS: Using data from 86 patients with International Classification of Diseases-10 diagnosis of depression, we calculated a ratio score representing IL-6 activity/bioavailability using serum IL-6, soluble IL-6 receptor (sIL-6R), and soluble glycoprotein 130 levels. We tested the relationship of this novel biomarker with 12 cytokines using correlation analyses and with cognitive and clinical measures using multivariable linear regression, following z-transformation of all immune exposures.RESULTS: The novel measure of IL-6 activity/bioavailability was correlated with IL-6 (r=0.42, P=0.03), C-reactive protein (CRP) (r=0.42, P=0.03), sIL-6R (r=0.91, P<0.01), and tumour necrosis factor alpha (r=0.43, P=0.03). The IL-6 activity/bioavailability measure was associated with higher somatic symptoms of depression (β=1.09; 95% CI 0.30, 1.88; PFDR=0.01), fatigue (β=4.34; 95% CI 1.26, 7.42; PFDR=0.03), depression severity (β=3.06; 95% CI 0.71, 5.40; P=0.02), poorer quality of life (β=-0.07; 95% CI -0.13, -0.01; PFDR=0.045), and decreased psychomotor speed (β=-5.46; 95% CI -9.09, -1.84; PFDR=0.01),. There was little evidence of associations with reaction time, anhedonia, anxiety, emotional perception and recall, executive function, and sustained attention (Ps>0.05). The effect estimates for the associations of the novel measure with depression outcomes were comparable to those for individual immune proteins (i.e., IL-6, CRP, sIL-6R).CONCLUSION: A novel multi-protein-derived measure of IL-6 activity/bioavailability shows robust associations with various inflammation-related clinical and cognitive outcomes in depression and performs well in comparison to single inflammatory proteins. We need replication of these findings in other samples, experiments for mechanistic validity of this novel biomarker, and clinical studies to assess its usefulness as a marker of illness risk and prognosis.

The relationship between plasma interleukin-6 and cognition based on curve correlation in drug-naïve patients with major depressive disorder

Linking peripheral IL-6, IL-1 and hypocretin-1 with cognitive impairment from major depression

Increased Plasma Levels of IL-6 Are Associated with Striatal Structural Atrophy in Major Depressive Disorder Patients with Anhedonia

Sex differences in the association of plasma cytokines and neurocognition in first-episode major depressive disorder

Association of Anhedonia with Brain-Derived Neurotrophic Factor and Interleukin-10 in Major Depressive Disorder

Sex Difference in IL-6 Modulation of Cognition among Chinese Individuals with Major Depressive Disorder

Inflammation-related abnormal dynamic brain activity correlates with cognitive impairment in first-episode, drug-naïve major depressive disorder

Ndt_a_202329 1695..1700

Relationship of interleukin 6 with depression

A novel biomarker of interleukin 6 activity and clinical and cognitive outcomes in depression

Association Between Increased Serum Interleukin-8 Levels and Improved Cognition in Major Depressive Patients with SSRIs

Plasma metabolites were associated with spatial working memory in major depressive disorder

The Level of IL-6 Was Associated with Sleep Disturbances in Patients with Major Depressive Disorder

Relaitonship of mean platelet volume to MDD: a retrospecitve study

IL-6 and IL-8 are likely associated with psychological status in treatment naïve general population

Interleukin-6 is correlated with amygdala volume and depression severity in adolescents and young adults with first-episode major depressive disorder

Comparisons of Serum Interleukin-8 Levels in Major Depressive Patients With Drug-Free Versus SSRIs Versus Healthy Controls

Role of inflammation in depression and anxiety: Tests for disorder specificity, linearity and potential causality of association in the UK Biobank

The relationship between plasma cytokine levels and antidepressant response in patients with first-episode major depressive disorder

The meta-analysis on the correlation between depression and interleukin-6

The effect of inflammation markers on cortical thinning in major depressive disorder: A possible mediator of depression and cortical changes